The Stroud Foundation was featured in the Fairfield Echo on Thursday, February 10, 2011. Click on READ MORE to view the article.

Pathwork® Tissue of Origin Test Clinical Utility Study
Presented at ASCO GI Symposium
Test Impacts Diagnosis and Management for Majority of Patients
Redwood City, CA, January 24, 2011 – Pathwork Diagnostics, Inc., a privately held molecular
diagnostics company focused on oncology, announced today that results from a decision impact
study of its Tissue of Origin Test were presented this weekend …

Pathwork® Tissue of Origin Test for FFPE Cleared by
U.S. Food and Drug Administration
Molecular profiling test utilizes common clinical specimen type
to help identify cancers
REDWOOD CITY, Calif., June 15, 2010 – Pathwork Diagnostics Inc., a molecular diagnostics
company focused on oncology, today announced the U.S. Food and Drug Administration (FDA)
cleared the Pathwork® Tissue of Origin Test for formalin-fixed, …

Published in the New York Times- March 10, 2009
By: Andrew Pollack
When Jo Symons was found to have cancer, there was an extra complication: doctors could not tell what type of cancer she had.
Tumors were found in her neck, chest and lymph nodes. But those tumors had spread there from someplace else, and her doctors could …